The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Increase the proportion of ischemic stroke patients that receive alteplase or EVT by 5% Reduce the time to treatment for both alteplase and EVT Reduce the door-to-needle time for alteplase treatment ...

On February 27, 2025, the Emergency Department team at Mercer Health was recognized by the Ohio State University Wexner ...

As stroke remains one of the leading causes of long-term disability and death worldwide, finding a more efficient and effective treatment is critical for improving patient outcomes and reducing ...

In the United States alone, more than 795,000 people experience a stroke each year, which is about one in every 40 seconds, ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...